CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO


24-May-2011
Cerilliant Introduces New Atomoxetine-D7 HCl Stable-Labeled Internal Standard & Atomoxetine HCl Certified Spiking Solution®

Atomoxetine-D7 HCl, 100 µg/mL A-093
100 ug/mL (as free base) in Methanol

A stable-labeled internal standard suitable for numerous GC/MS and LC/MS applications for atomoxetine from clinical toxicology and urine drug testing to forensic analysis and isotope dilution methods. Atomoxetine, marketed in the US under the trade name Strattera®, is a drug used in the treatment of attention-deficit hyperactivity disorder (ADHD).

Atomoxetine HCl, 1.0 mg/mL A-095
1.0 mg/mL (as free base) in Methanol

Atomoxetine is an attention-deficit hyperactivity disorder (ADHD) drug marketed in the US under the trade name Strattera®. This Certified Spiking Solution® is suitable for use in numerous testing applications such as clinical toxicology, forensic analysis, pharmaceutical research, urine drug testing, or calibrator preparation.

In addition to atomoxetine and its stable-labeled internal standard Atomoxetine-D7 HCl, Cerilliant offers Snap-N-Spike® solution standards of other ADHD drugs including methylphenidate as well as numerous stimulants, performance-enhancing drugs, and their metabolites and internal standards, such as modafinil, selegiline, amphetamine, diethylpropion, and clenbuterol.


Cerilliant Certified Solution Standards and Certified Spiking Solutions are manufactured to the highest industry standards. We are accredited to ISO Guide 34 and ISO/IEC 17025 & certified to ISO 13485 and ISO 9001. Our quality system also incorporates cGMP and GLP requirements


All New Product Announcements


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn